Second-line Treatment of Advanced Non-small Cell Lung Cancer Non-oncogene Addicted: New Treatment Algorithm in the Era of Novel Immunotherapy.

IF 3.2 Q2 Pharmacology, Toxicology and Pharmaceutics Current clinical pharmacology Pub Date : 2018-01-01 DOI:10.2174/1574884713666180711160008
Cesare Gridelli, Paolo Antonio Ascierto, Francesco Grossi, Editta Baldini, Adolfo Favaretto, Maria Chiara Garassino, Alessandro Morabito, Maria Rita Migliorino, Antonio Rossi, Filippo de Marinis
{"title":"Second-line Treatment of Advanced Non-small Cell Lung Cancer Non-oncogene Addicted: New Treatment Algorithm in the Era of Novel Immunotherapy.","authors":"Cesare Gridelli,&nbsp;Paolo Antonio Ascierto,&nbsp;Francesco Grossi,&nbsp;Editta Baldini,&nbsp;Adolfo Favaretto,&nbsp;Maria Chiara Garassino,&nbsp;Alessandro Morabito,&nbsp;Maria Rita Migliorino,&nbsp;Antonio Rossi,&nbsp;Filippo de Marinis","doi":"10.2174/1574884713666180711160008","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Most patients with advanced non-small cell lung cancer (NSCLC) have a poor prognosis and receive limited benefit from conventional treatments, especially in later lines of therapy. In recent years, several novel therapies have been approved for second- and third-line treatment of advanced NSCLC beyond old chemotherapy agents (docetaxel and pemetrexed) and the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI, erlotinib). In particular, the new antiangiogenetics (nindetanib and ramucirumab) in combination with docetaxel and immunotherapy (nivolumab, pembrolizumab and atezolizumab) have been recently approved and represent new treatment options.</p><p><strong>Methods: </strong>The Italian Association of Thoracic Oncology (AIOT) organized five meetings in different Italian regions representing North, Middle and South of the country in order to discuss the issue.</p><p><strong>Results: </strong>In light of these new approvals, it is valuable to understand the uptake of these new therapies in routine clinical practice and their impact on patient care. With these treatment options to define an appropriate algorythm is object of debate.</p><p><strong>Conclusion: </strong>The present paper discusses the old and new treatment opportunities, proposing a shared algorithm for second-line setting in advanced NSCLC.</p>","PeriodicalId":10746,"journal":{"name":"Current clinical pharmacology","volume":null,"pages":null},"PeriodicalIF":3.2000,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1574884713666180711160008","citationCount":"11","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current clinical pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1574884713666180711160008","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 11

Abstract

Background: Most patients with advanced non-small cell lung cancer (NSCLC) have a poor prognosis and receive limited benefit from conventional treatments, especially in later lines of therapy. In recent years, several novel therapies have been approved for second- and third-line treatment of advanced NSCLC beyond old chemotherapy agents (docetaxel and pemetrexed) and the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI, erlotinib). In particular, the new antiangiogenetics (nindetanib and ramucirumab) in combination with docetaxel and immunotherapy (nivolumab, pembrolizumab and atezolizumab) have been recently approved and represent new treatment options.

Methods: The Italian Association of Thoracic Oncology (AIOT) organized five meetings in different Italian regions representing North, Middle and South of the country in order to discuss the issue.

Results: In light of these new approvals, it is valuable to understand the uptake of these new therapies in routine clinical practice and their impact on patient care. With these treatment options to define an appropriate algorythm is object of debate.

Conclusion: The present paper discusses the old and new treatment opportunities, proposing a shared algorithm for second-line setting in advanced NSCLC.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
晚期非小细胞肺癌非癌基因成瘾的二线治疗:新型免疫治疗时代的新治疗算法
背景:大多数晚期非小细胞肺癌(NSCLC)患者预后较差,从常规治疗中获益有限,特别是在后期治疗中。近年来,除了老的化疗药物(多西紫杉醇和培美曲塞)和表皮生长因子受体(EGFR)酪氨酸激酶抑制剂(TKI、埃洛替尼)外,一些新疗法已被批准用于晚期NSCLC的二线和三线治疗。特别是,新的抗血管遗传学(nindetanib和ramucirumab)联合多西他赛和免疫治疗(nivolumab, pembrolizumab和atezolizumab)最近已获得批准,代表了新的治疗选择。方法:意大利胸肿瘤协会(AIOT)在意大利北部、中部和南部的不同地区组织了五次会议,以讨论这一问题。结果:鉴于这些新的批准,了解这些新疗法在常规临床实践中的应用及其对患者护理的影响是有价值的。用这些治疗方案定义一个合适的算法是争论的对象。结论:本文讨论了晚期NSCLC的新老治疗机会,提出了一种二线治疗的共享算法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Current clinical pharmacology
Current clinical pharmacology PHARMACOLOGY & PHARMACY-
CiteScore
3.60
自引率
0.00%
发文量
0
期刊介绍: Current Clinical Pharmacology publishes frontier reviews on all the latest advances in clinical pharmacology. The journal"s aim is to publish the highest quality review articles in the field. Topics covered include: pharmacokinetics; therapeutic trials; adverse drug reactions; drug interactions; drug metabolism; pharmacoepidemiology; and drug development. The journal is essential reading for all researchers in clinical pharmacology.
期刊最新文献
Assessment of the Efficacy of Withania somnifera Root Extract in Patients with Generalized Anxiety Disorder: A Randomized Double-blind Placebo- Controlled Trial. Meet Our Editorial Board Member Comparative effectiveness of Agmatine and Choline treatment in rats with cognitive impairment induced by AlCl3 and Forced Swim Stress. Meet Our Associate Editorial Board Member Meet Our Editorial Board Member
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1